Clinical Trial Update: Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 [Phase 3]

View source ↗

Summary

Phase 3 long-term access program update for mepolizumab in subjects from a prior study; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Churg-strauss Syndrome
• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Status: COMPLETED | Results posted: 2024-03-12